Tomohiro Kimura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tomohiro Kimura has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Hermann M. Schatzl
Calgary Prion Research Unit, University of Calgary, Calgary, AB T2N 4Z6, Canada
1 shared publication - Katsumi Doh-Ura
Department of Neurochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan
1 shared publication Ken Kodama
Neopharma Japan Co., Ltd., Japan
1 shared publicationKensuke Ishikawa
Department of Prion Research, Tohoku University Graduate School of Medicine, Sendai, Japan
1 shared publication- Kenta Teruya
Department of Neurochemistry, Tohoku University Graduate School of Medicine, Sendai, Japan
1 shared publication Kiwamu Takahashi
SBI Pharmaceuticals Co., Ltd., Japan
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 697, 108721
Heterozygous disruption of ALAS1 in mice causes an accelerated age-dependent reduction in free heme, but not total heme, in skeletal muscle and liver
- 1 January 2021
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 697, 108721
Open AccessHeterozygous disruption of ALAS1 in mice causes an accelerated age-dependent reduction in free heme, but not total heme, in skeletal muscle and liver
- Open Access
- 14 February 2010
- Published by Wiley in FEBS Letters
- Vol. 584 (6) , 1193-1198
GABAA receptor subunit β1 is involved in the formation of protease‐resistant prion protein in prion‐infected neuroblastoma cells
γ‐Aminobutyric acid type A (GABAA) receptor β1 (gabrb1), a subunit of GABAA receptors involved in inhibitory effects on neurotransmission, was found to associate with the formation of protease‐resistant prion protein in prion‐infected neuroblastoma cells. Silencing of gabrb1 gene expression significantly decreased the abnormal prion protein level but paradoxically increased the normal prion protein level. Treatment with a gabrb1‐specific inhibitor, salicylidene salicylhydrazide, dose‐dependently decreased the abnormal prion protein level, but silencing of other GABAA receptor subunits’ gene expression and treatments with the receptor antagonists and agonists did not. Therefore, gabrb1 involvement in abnormal prion protein formation is independent of GABAA receptors.
- 14 February 2010
- Published by Wiley in FEBS Letters
- Vol. 584 (6) , 1193-1198
Open AccessGABAA receptor subunit β1 is involved in the formation of protease‐resistant prion protein in prion‐infected neuroblastoma cells
γ‐Aminobutyric acid type A (GABAA) receptor β1 (gabrb1), a subunit of GABAA receptors involved in inhibitory effects on neurotransmission, was found to associate with the formation of protease‐resistant prion protein in prion‐infected neuroblastoma cells. Silencing of gabrb1 gene expression significantly decreased the abnormal prion protein level but paradoxically increased the normal prion protein level. Treatment with a gabrb1‐specific inhibitor, salicylidene salicylhydrazide, dose‐dependently decreased the abnormal prion protein level, but silencing of other GABAA receptor subunits’ gene expression and treatments with the receptor antagonists and agonists did not. Therefore, gabrb1 involvement in abnormal prion protein formation is independent of GABAA receptors.